Competition Appeal Tribunal upholds Competition and Markets Authority’s decision to fine Lexon £1.2m for breach of competition law in relation to pricing of nortriptyline

Last year, the Competition and Markets Authority had found that from 2015 to 2017, when cost of the drug was decreasing, Lexon, along with King Pharmaceuticals and Alissa Healthcare Research, had illegally shared commercially sensitive information in an attempt to drive up prices

PharmaTimes